A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Trial Profile

A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Lampalizumab (Primary)
  • Indications Dry age-related macular degeneration
  • Focus Registrational; Therapeutic Use
  • Acronyms CHROMA
  • Sponsors Roche
  • Most Recent Events

    • 12 Dec 2017 This trial has been discontinued in Germany.
    • 02 Dec 2017 This trial was discontinued in Hungary, according to European Clinical Trials Database.
    • 07 Nov 2017 Planned End Date changed from 31 Dec 2018 to 27 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top